Contraindicated (one)pentobarbital will reduce the level or outcome of cariprazine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. CYP3A4 is responsible for the development and elimination of cariprazine's active metabolites.
pentobarbital will decrease the extent or impact of nelfinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
pentobarbital will reduce the level or influence of erlotinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will lessen the extent or effect of tamoxifen by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
pentobarbital will lessen the extent or influence of solifenacin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
pentobarbital raises toxicity of ifosfamide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. CYP3A4 inducers may possibly raise the metabolism of ifosfamide to its Lively alkylating metabolites.
pentobarbital will decrease the level or impact of maraviroc by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will reduce the extent or result of fentanyl by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Closely. Coadministration of fentanyl with CYP3A4 inducers could lead to a lessen in fentanyl plasma concentrations, deficiency of efficacy or, probably, development of a withdrawal syndrome in the client who may have made physical dependence to fentanyl.
pentobarbital will reduce the level or impact of felodipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
Keep track of Closely (one)pentobarbital will raise the stage or influence of clopidogrel by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will lessen the extent or influence of imatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Unknown.
pentobarbital will reduce the extent or result of norgestrel by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Carefully. Moderate CYP3A4 inducers might decrease progestin focus; take into account utilization of additional barrier procedures
Phenytoin and barbiturate blood degrees needs to be monitored more commonly if provided concurrently; here effect of barbiturates on phenytoin metabolism described for being variable; sodium valproate and valproic acid appear to lessen barbiturate metabolism; check barbiturate blood ranges and make appropriate dosage changes as needed
Monoamine oxidase inhibitors (MAOI) could inhibit barbiturate metabolism and extend barbiturate results; check intently